Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.28 -0.07 (-0.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Another Tough Day For Markets
The stock market resumed its negativism today mainly linked to fear of inflation and higher interest rates, on the argument that the most dangerous thing to believe is “it's different this time.” 
Via Talk Markets
Sanofi-Regeneron Tout New Data For Dupixent From Pediatric Asthma Trial
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have unveiled detailed results from a Phase 3 trial evaluating Dupixent... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Sanofi-GSK's COVID-19 Vaccine Candidate Reports Success In Mid-Stage Study
Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of... 
Via Benzinga
Exposures COVID-19
Daily Stock Analysis: Sanofi (SNY)
Sanofi's price per share closed at $51.50 yesterday. One year ago its price was $49.87. 
Via Talk Markets
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving lower for much of the week before coming back up strongly in the final session. Some of the weakness may be traced back... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving broadly lower for much of the week before coming back up strongly in the final session. Some of the... 
Via Benzinga
Exposures Product Safety
15 European Dividend Aristocrats To Diversify Your Portfolio
In general, Dividend Aristocrats are the foundation for the portfolios of most serious dividend growth investors. European Dividend aristocrats are typically blue chip stocks that... 
Via Benzinga
Novavax Reports Positive Data From Animal Trial of Its COVID-19/Flu Combo Shot
Human trials of the combination vaccine are expected to start later this year. 
Via The Motley Fool
Exposures COVID-19
Is Sanofi a Good Buy in 2021?
You might want to add this international blue-chip stock to your portfolio. 
Via The Motley Fool
FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic
The FDA has published a roadmap for working through the backlog of facility inspections built up during the pandemic when it postponed all routine inspections in March... 
Via Benzinga
Exposures Product Safety
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples... 
Via Benzinga
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
Could AstraZeneca and Sanofi Win Big in RSV?
The companies have a promising RSV candidate. 
Via The Motley Fool
Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed... 
Via Benzinga
Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy
Avrobio Inc (NASDAQ: AVRO) has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers BioVie (NASDAQ:BIVI) shares increased by 12.96% to $19.78 during Monday's pre-market session. The company's market cap stands at $275.2 million. Ocugen (... 
Via Benzinga
22 Stocks Moving in Monday's Pre-Market Session
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) rose 58.3% to $78.90 in pre-market trading. Nicholas Jason Singer disclosed a 9.13% passive stake in Brooklyn... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
70 Firms Going Ex-Dividend Next Week, Including Walmart, BP And Pfizer
There are several well known large cap stocks going ex-dividend next week. Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to... 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
Moderna Tries To Boost COVID-19 Vaccine Supply Chain To Produce 3B Doses Annually
Moderna Inc (NASDAQ: MRNA) plans to produce up to 3 billion doses in 2022, doubling capacity at contract sites in Switzerland and Spain run by Lonza Group... 
Via Benzinga
Exposures COVID-19
Moderna Stock Near Breakout As Company Boosts Its Covid Vaccines Outlook
Moderna boosted its forecast for Covid vaccine doses in 2021 and 2022, in a move early Thursday that could send Moderna stock into a breakout. 
Via Investor's Business Daily
Exposures COVID-19
Sanofi SA (SNY) Q1 2021 Earnings Call Transcript
SNY earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran
Sanofi SA (NASDAQ: SNY) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its... 
Via Benzinga
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
Big Earnings Week Ahead To Close April In Style
Last week, the Dow Jones Industrial Average, S&P 500 and Nasdaq broke multiweek winning streaks with modest losses despite Friday's rally. This week's earnings will... 
Via Benzinga
Topics Stocks
Exposures US Equities
Sanofi Steps In For Fill-Finish 200M Doses Of Moderna's COVID-19 Vaccine
As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY) has entered an agreement with Moderna Inc (NASDAQ: MRNA)... 
Via Benzinga
Exposures COVID-19
Sanofi-AstraZeneca's Nirsevimab Hits Primary Endpoint Goal In Late-Stage RSV Disease In Infants
Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc’s (NASDAQ: AZN) monoclonal antibody (mAb) nirsevimab has reached its primary endpoint in a... 
Via Benzinga
BioN­Tech CFO Sees Scope For Additional Pro­duc­tion Sites To Meet De­mand For COVID-19 Shots: Reuters
Pfizer Inc's (NYSE: PFE) COVID-19 vaccine partner BioNTech SE (NASDAQ: BNTX) is not ruling out further capacity expansion and new production... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.